Impact of the patient population on the risk for heparin-induced thrombocytopenia.
about
Heparin induced thrombocytopenia: diagnosis and management updateHeparin-induced thrombocytopenia in solid organ transplant recipients: The current scientific knowledgeHeparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrumsImpact of thromboprophylaxis across the US acute care settingLearning classification models with soft-label informationLaboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulantsPF4/heparin complexes are T cell-dependent antigens.Determinants of PF4/heparin immunogenicityAnti-PF4/heparin antibodies associated with repeated hemofiltration-filter clotting: a retrospective study.Pharmacodynamic and efficacy profile of TGN 255, a novel direct thrombin inhibitor, in canine cardiopulmonary bypass and simulated mitral valve repair.The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushesAnti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopeniaOptimization of a murine immunization model for study of PF4/heparin antibodies.Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature.Utility of ELISA optical density values and clinical scores for the diagnosis of and thrombosis prediction in heparin-induced thrombocytopenia.Prospective multicentre cohort study of heparin-induced thrombocytopenia in acute ischaemic stroke patients.Sample-efficient learning with auxiliary class-label informationTreatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Heparin induced thrombocytopenia: case presentation and review.Early post-operative thrombosis of the prosthetic mitral valve in patient with heparin-induced thrombocytopenia.Argatroban dose reductions for suspected heparin-induced thrombocytopenia complicated by child-pugh class C liver disease.Heparin-induced thrombocytopenia in the pediatric population: a review of current literatureBlood utilization in patients with burn injury and association with clinical outcomes (CME).Learning medical diagnosis models from multiple experts.High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypassEmphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.Pulmonary embolism caused by delayed heparin-induced thrombocytopenia in a patient who received prophylactic LMWH.Learning classification models from multiple experts.Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4.B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia.Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring systemFrom clinical reasoning to effective clinical decision making-new training methods.Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophagesHeparin-induced thrombocytopenia in a non-heparin-naive patient: a case reportClinical and laboratory characteristics associated with a high optical density anti-platelet factor 4 ELISA testMechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery.A case of enoxaparin-induced thrombocytopaenia during treatment of acute myocardial infarction.Heparin-induced thrombocytopenia among patients of a comprehensive cancer center.The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery.Perioperative care in an adolescent patient with heparin-induced thrombocytopenia for placement of a cardiac assist device and heart transplantation: case report and literature review
P2860
Q24647207-F73CEE7E-3FE7-4F09-91BC-E47ECDA15BACQ26751442-5CD67E3C-26C4-4493-B6E1-EB8A2F0703CCQ26799395-7A76C58D-DCE8-4A1A-9FF1-B2F6E987614BQ28651190-2A4A38E7-8635-4FED-A2D1-A68CF87730B9Q28658620-946D89CE-1870-448F-977E-12E2D6443987Q33349870-A40E3E5B-919F-430E-A698-43D5C7C5B90AQ33365918-A108D678-3EFC-4C04-9465-8F7EAC10463FQ33376629-AB1DEA5B-524C-4697-9E47-53D0A8A685AEQ33380088-983FA999-9E8A-4A27-9621-66D2944EBABEQ33380778-F805A0E4-0BDB-4DD8-A3BF-02F99E3E1886Q33381352-5453B4F5-8C9D-4DB1-A200-FA5512A972E4Q33381447-FC40FACA-9FBC-4DB0-99AC-D4571F165BE0Q33383456-002D61D8-4FED-4F21-8BDB-9F3999E63B75Q33388490-A8A3F780-C5BC-4F6F-8109-84FB99DB72E1Q33393683-859F9CDC-633F-44F0-AC21-FD6394220DC0Q33395782-CB3FAA32-2DD1-4D10-AE90-061685E38C75Q33398903-B9586EA6-5A3D-492A-B9B5-AFC69CBBD9AEQ33399580-97E30A3F-DE32-409F-86BA-DDBD30D82FD8Q33400029-83722541-6BFF-4390-B70B-869AB7DA450FQ33400235-F9D8339D-A431-417A-BC8B-5B36E2A4C9B6Q33403844-DF313A17-96C7-40C3-B442-4C7264F17FA7Q33404178-9E59C9AD-8247-4652-9D96-C7EC0410B9BDQ33405055-44463FB0-12C0-4645-A161-45ADCF7A20B4Q33405213-9EF204A7-1702-41AE-954C-393CDE7A217EQ33405980-7FFF6655-1E6C-43BC-AF43-37F9D4F2E840Q33406904-50614BEF-2918-4C5D-87E3-4EAEC5669910Q33406965-8DC8BAEB-B6C4-4F5B-9B84-1A23F5FB5292Q33410334-76326EEB-CB90-4861-B963-A0BBBD7A255CQ33410765-13E4C352-4FA1-4FBE-A5B5-87569E2925BCQ33412220-703CDED3-A500-467B-80AF-FF83FFA4D399Q33418994-F77420B3-F3CA-4C89-9686-24D4DA60FF20Q33422677-6EBBCB99-7F29-45B5-8613-31C766E2AFABQ33422720-0EEA0FFC-D9CD-41EA-9DFB-0BB5136BDF7FQ33425375-908F3F88-CE75-4975-9A56-A961114C0F64Q33428198-F6B94F62-651E-4B92-92B7-6774ECF6D20BQ33428351-878B206C-3042-408D-AC9E-7DD9B9E3F551Q33431523-363CCE69-5453-441C-9B3D-5D243695A377Q33434343-BC731DDA-553E-4CC7-93D5-BD73F723F5A2Q33435819-C3E7CBB9-C37A-43E9-AF4A-35C4F080059FQ33439709-EC9105A1-F846-4CB2-BEB9-DD2A71E0F891
P2860
Impact of the patient population on the risk for heparin-induced thrombocytopenia.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Impact of the patient population on the risk for heparin-induced thrombocytopenia.
@ast
Impact of the patient population on the risk for heparin-induced thrombocytopenia.
@en
Impact of the patient population on the risk for heparin-induced thrombocytopenia.
@nl
type
label
Impact of the patient population on the risk for heparin-induced thrombocytopenia.
@ast
Impact of the patient population on the risk for heparin-induced thrombocytopenia.
@en
Impact of the patient population on the risk for heparin-induced thrombocytopenia.
@nl
prefLabel
Impact of the patient population on the risk for heparin-induced thrombocytopenia.
@ast
Impact of the patient population on the risk for heparin-induced thrombocytopenia.
@en
Impact of the patient population on the risk for heparin-induced thrombocytopenia.
@nl
P2093
P1433
P1476
Impact of the patient population on the risk for heparin-induced thrombocytopenia
@en
P2093
Horsewood P
Sheppard JA
Simpson PJ
Warkentin TE
P304
P407
P577
2000-09-01T00:00:00Z